Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
Antiplatelet therapy with clopidogrel is widely used in patients with coronary artery disease, but the recent development of the new P2Y12 receptor antagonists prasugrel and ticagrelor will increase treatment options. An overview of systematic reviews was performed to summarize available evidence on...
Main Author: | Steiner-Boeker, Sabine |
---|---|
Language: | en |
Published: |
2011
|
Subjects: | |
Online Access: | http://hdl.handle.net/10393/20176 |
Similar Items
-
Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011) -
Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011) -
Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells
by: Omar Elaskalani, et al.
Published: (2020-01-01)